logo

Clinical Trial Results

Share

pharmadown-dec17.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharmaup-dec17.jpg The following are some of today's top gainers in the pharma/biotech sector.

Eli Lilly and Co. (LLY) said Monday that Taltz, or ixekizumab, met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira, or adalimumab, in patients with active psoriatic arthritis or PsA who are biologic disease-modifying...

pharmadown-dec13.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharmaup-dec13.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-dec12.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmadown-dec11.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharmaup-dec11.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmaup-dec10.jpg The following are some of today's top gainers in the pharma/biotech sector.

pharmadown-dec06.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharmaup-dec06.jpg The following are some of today's top gainers in the pharma/biotech sector.

Seattle Genetics, Inc. (SGEN) and Japan's Takeda Pharmaceutical Company Limited announced late Monday positive data from the ECHELON-2 phase 3 clinical trial for ADCETRIS (Brentuximab Vedotin) in frontline treatment of CD30-Expressing Peripheral T-Cell Lymphomas. The data demonstrated that frontline...

pharma-022817_03dec18.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

pharma-020918_03dec18.jpg The following are some of today's top gainers in the pharma/biotech sector.

Alkermes plc (ALKS) announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), an investigational, once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia. In the study, ALKS 3831 met the pre-specified co-primary...

Follow RTT